Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 7, 2016, Pages E874-E883

  Brackett, Craig M ^a   Kojouharov, Bojidar ^a   Veith, Jean ^a   Greene, Kellee F ^a   Burdelya, Lyudmila G ^a   Gollnick, Sandra O ^a   Abrams, Scott I ^a   Gudkov, Andrei V ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CLEVELAND BIOLABS INC   (United States)

Author keywords

Breast cancer; Cancer immunotherapy; Colorectal cancer; Innate immunity; Liver

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; ENTOLIMOD; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT3 PROTEIN; PEPTIDE; TOLL LIKE RECEPTOR 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; IMMUNOLOGICAL MEMORY; LIVER METASTASIS; LYMPHOCYTE DEPLETION; METASTASIS; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR IMMUNITY; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; COLON TUMOR; DRUG EFFECTS; EXPERIMENTAL MAMMARY NEOPLASM; IMMUNOLOGY; NATURAL KILLER CELL; NEOPLASM METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; KILLER CELLS, NATURAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM METASTASIS; PEPTIDES; TOLL-LIKE RECEPTOR 5;

EID: 84958771074     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1521359113     Document Type: Article

References (78)

1. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol 12(4):269-281.
2. Puré E, Allison JP, Schreiber RD (2005) Breaking down the barriers to cancer immunotherapy. Nat Immunol 6(12):1207-1210.
3. Drobits B, et al. (2012) Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 122(2): 575-585.
4. O'Sullivan T, et al. (2012) Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 209(10):1869-1882.
5. Smyth MJ, et al. (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191(4):661-668.
6. Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13(5):552-559.
7. Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2(8):675-680.
8. Rakoff-Nahoum S, Medzhitov R (2009) Toll-like receptors and cancer. Nat Rev Cancer 9(1):57-63.
9. Stanley MA (2002) Imiquimod and the imidazoquinolones: Mechanism of action and therapeutic potential. Clin Exp Dermatol 27(7):571-577.
10. Adams S, et al. (2008) Immunization of malignant melanoma patients with full-length NYESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181(1):776-784.
11. Khan AL, Heys SD, Eremin O (1995) Synthetic polyribonucleotides: Current role and potential use in oncological practice. Eur J Surg Oncol 21(2):224-227.
12. Manegold C, et al. (2008) Randomized phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 26(24):3979-3986.
13. Huang B, et al. (2007) Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 67(9):4346-4352.
14. Pidgeon GP, et al. (1999) The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 81(8): 1311-1317.
15. Harmey JH, et al. (2002) Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 101(5):415-422.
16. Fan H, et al. (2012) Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice. Clin Cancer Res 18(20):5628-5638.
17. Le Mercier I, et al. (2013) Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 73(15):4629-4640.
18. Palamara F, et al. (2004) Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 173(5):3051-3061.
19. Sfondrini L, et al. (2006) Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 176(11):6624-6630.
20. Garaude J, Kent A, van Rooijen N, Blander JM (2012) Simultaneous targeting of Tolland nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 4(120):120ra16.
21. Cai Z, et al. (2011) Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 71(7):2466-2475.
22. Rhee SH, Im E, Pothoulakis C (2008) Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 135(2):518-528.
23. Burdelya LG, et al. (2012) Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: Implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys 83(1):228-234.
24. Soto LJ, 3rd, et al. (2003) Attenuated Salmonella typhimurium prevents the establishment of unresectable hepatic metastases and improves survival in a murine model. J Pediatr Surg 38(7):1075-1079.
25. Yam C, et al. (2010) Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res 164(2): 248-255.
26. Burdelya LG, et al. (2013) Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci USA 110(20):E1857-E1866.
27. Carvalho FA, Aitken JD, Gewirtz AT, Vijay-Kumar M (2011) TLR5 activation induces secretory interleukin-1 receptor antagonist (sIL-1Ra) and reduces inflammasomeassociated tissue damage. Mucosal Immunol 4(1):102-111.
28. Vijay-Kumar M, et al. (2008) Toll-like receptor 5-deficient mice have dysregulated intestinal gene expression and nonspecific resistance to Salmonella-induced typhoidlike disease. Infect Immun 76(3):1276-1281.
29. Burdelya LG, et al. (2008) An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320(5873):226-230.
30. Adjei A (2011) Entolimod in treating patients with locally advanced or metastatic solid tumors that cannot be removed by surgery. Clinical trial no. NCT01527136. Avaliable at ClinicalTrials.gov. Accessed October 24, 2015.
31. Krivokrysenko VI, et al. (2015) The Toll-like receptor 5 agonist entolimod mitigates lethal acute radiation syndrome in non-human primates. PLoS One 10(9):e0135388.
32. Yang H, et al. (2015) The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget, 10.18632/oncotarget.6500.
33. Hossain MS, Ramachandiran S, Gewirtz AT, Waller EK (2014) Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice. PLoS One 9(5): e96165.
34. Lise M, Mocellin S, Pilati P, Nitti D (2005) Colorectal liver metastasis: Towards the integration of conventional and molecularly targeted therapeutic approaches. Front Biosci 10:3042-3057.
35. Kim S, et al. (2002) In vivo developmental stages in murine natural killer cell maturation. Nat Immunol 3(6):523-528.
36. Bahjat KS, et al. (2007) Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease. J Immunol 179(11):7376-7384.
37. Dupaul-Chicoine J, et al. (2015) The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity 43(4):751-763.
38. Moretta L, et al. (2006) Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 214:219-228.
39. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP (1999) Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu Rev Immunol 17:189-220.
40. Gerosa F, et al. (2002) Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195(3):327-333.
41. Mocikat R, et al. (2003) Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19(4):561-569.
42. Adam C, et al. (2005) DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 106(1):338-344.
43. Liu X, et al. (2014) Flagellin-induced expression of CXCL10 mediates direct fungal killing and recruitment of NK cells to the cornea in response to Candida albicans infection. Eur J Immunol 44(9):2667-2679.
44. Luster AD, Ravetch JV (1987) Biochemical characterization of a gamma interferoninducible cytokine (IP-10). J Exp Med 166(4):1084-1097.
45. Loetscher M, et al. (1996) Chemokine receptor specific for IP10 and mig: Structure, function, and expression in activated T-lymphocytes. J Exp Med 184(3):963-969.
46. Loetscher M, Loetscher P, Brass N, Meese E, Moser B (1998) Lymphocyte-specific chemokine receptor CXCR3: Regulation, chemokine binding and gene localization. Eur J Immunol 28(11):3696-3705.
47. Martín-Fontecha A, et al. (2004) Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5(12):1260-1265.
48. Wendel M, Galani IE, Suri-Payer E, Cerwenka A (2008) Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 68(20):8437-8445.
49. Farber JM (1990) A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sci USA 87(14):5238-5242.
50. Luster AD, Unkeless JC, Ravetch JV (1985) Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315(6021):672-676.
51. Jain A, et al. (2003) Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol 10(7):810-820.
52. Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58(7): 1486-1493.
53. Leigh ND, et al. (2014) A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity. PLoS One 9(1):e85587.
54. Sturge CR, et al. (2013) TLR-independent neutrophil-derived IFN-γ is important for host resistance to intracellular pathogens. Proc Natl Acad Sci USA 110(26):10711-10716.
55. Crouse J, Xu HC, Lang PA, Oxenius A (2015) NK cells regulating T cell responses: Mechanisms and outcome. Trends Immunol 36(1):49-58.
56. Terabe M, Berzofsky JA (2008) The role of NKT cells in tumor immunity. Adv Cancer Res 101:277-348.
57. Jordan MA, Fletcher J, Baxter AG (2004) Genetic control of NKT cell numbers. Immunol Cell Biol 82(3):276-284.
58. Ryan MH, Bristol JA, McDuffie E, Abrams SI (2001) Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope. J Immunol 167(8):4286-4292.
59. Barrett DM, Singh N, Porter DL, Grupp SA, June CH (2014) Chimeric antigen receptor therapy for cancer. Annu Rev Med 65:333-347.
60. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252-264.
61. Hinrichs CS, Rosenberg SA (2014) Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257(1):56-71.
62. O'Neill LA, Golenbock D, Bowie AG (2013) The history of Toll-like receptors - Redefining innate immunity. Nat Rev Immunol 13(6):453-460.
63. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5(10):987-995.
64. Geng D, et al. (2015) TLR5 ligand-secreting T cells reshape the tumor microenvironment and enhance antitumor activity. Cancer Res 75(10):1959-1971.
65. Rutkowski MR, et al. (2015) Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27(1):27-40.
66. Maghazachi AA (2003) G protein-coupled receptors in natural killer cells. J Leukoc Biol 74(1):16-24.
67. Salazar-Mather TP, Orange JS, Biron CA (1998) Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J Exp Med 187(1):1-14.
68. Khan IA, et al. (2006) CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection. PLoS Pathog 2(6):e49.
69. Riise RE, et al. (2015) TLR-stimulated neutrophils instruct NK cells to trigger dendritic cell maturation and promote adaptive T cell responses. J Immunol 195(3):1121-1128.
70. Huang X, et al. (2002) Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res 62(20):5727-5735.
71. Yoo JK, Cho JH, Lee SW, Sung YC (2002) IL-12 provides proliferation and survival signals to murine CD4+ T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J Immunol 169(7):3637-3643.
72. Curtsinger JM, Agarwal P, Lins DC, Mescher MF (2012) Autocrine IFN-γ promotes naive CD8 T cell differentiation and synergizes with IFN-a to stimulate strong function. J Immunol 189(2):659-668.
73. Vicente-Suarez I, Brayer J, Villagra A, Cheng F, Sotomayor EM (2009) TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol Lett 125(2):114-118.
74. Uematsu S, et al. (2008) Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol 9(7):769-776.
75. Honda K, Taniguchi T (2006) IRFs: Master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6(9):644-658.
76. Kanda N, Shimizu T, Tada Y, Watanabe S (2007) IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur J Immunol 37(2):338-350.
77. Harikumar KB, et al. (2014) K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5. Nat Immunol 15(3):231-238.
78. Ksienzyk A, et al. (2011) IRF-1 expression is essential for natural killer cells to suppress metastasis. Cancer Res 71(20):6410-6418.